A 38-year-old man with a history of intravenous drug use presents with jaundice, fatigue, and right upper quadrant pain for 2 weeks. He reports a tattoo done 6 months ago. Laboratory findings show ALT 3200 IU/L, AST 2800 IU/L, total bilirubin 9.5 mg/dL, INR 1.3, albumin 3.2 g/dL, and anti-HCV antibody positive. HCV RNA (quantitative) is 850,000 IU/mL. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient presents with **acute hepatitis C** — evidenced by recent high-risk exposures (IV drug use, tattoo 6 months ago), markedly elevated transaminases (ALT 3200, AST 2800), jaundice, and a positive anti-HCV antibody with detectable HCV RNA. The key management question is whether to start DAA therapy immediately or to observe first. ## Management of Acute Hepatitis C **Key Point:** In **acute HCV infection**, current AASLD/IDSA guidelines recommend a period of **watchful waiting (8–12 weeks)** before initiating antiviral therapy, because **15–45% of patients spontaneously clear the virus** during this window. Premature treatment would expose a significant proportion of patients to unnecessary medication. ### Why Supportive Care with Deferred Antiviral Therapy Is the Correct Next Step **High-Yield:** The standard approach in acute HCV (AASLD 2020, Harrison's Principles of Internal Medicine): 1. **Admit/monitor** for hepatic synthetic function (INR, albumin, bilirubin trends) 2. **Defer DAA therapy** for 8–12 weeks to allow spontaneous clearance 3. **Repeat HCV RNA** at 8–12 weeks — if still detectable, initiate DAA therapy 4. **Supportive care** (hydration, avoid hepatotoxins, rest) during the acute phase **Clinical Pearl:** Spontaneous clearance is more likely in symptomatic patients (jaundice is a favorable sign), younger patients, females, and those with IL28B CC genotype. This patient's symptomatic presentation (jaundice) actually increases the probability of spontaneous clearance, making watchful waiting even more appropriate. ### Why INR 1.3 and Albumin 3.2 Do Not Change This Decision These values reflect **acute hepatic inflammation**, not chronic decompensation. They are expected in severe acute hepatitis and are not contraindications to watchful waiting. They do, however, warrant **inpatient monitoring** to detect progression to acute liver failure. ## Why Each Distractor Is Wrong | Option | Reason | | --- | --- | | **Immediate DAA therapy (Option A)** | Premature in acute HCV. Guidelines recommend waiting 8–12 weeks for possible spontaneous clearance before committing to antiviral therapy. Immediate treatment is appropriate only in **chronic** HCV or if the patient fails to clear spontaneously. | | **Liver biopsy before therapy (Option B)** | Biopsy is **not indicated** in acute HCV management. Fibrosis staging does not alter the decision to observe first. Additionally, biopsy carries bleeding risk with INR 1.3. | | **Interferon-alpha + ribavirin (Option D)** | This regimen is **obsolete**. Interferon-based therapy has been replaced by DAAs due to superior efficacy (>95% SVR) and tolerability. Interferon is also relatively contraindicated in acute hepatitis with coagulopathy. | ## Monitoring During Watchful Waiting - **Repeat HCV RNA at 4 and 12 weeks** — if undetectable, spontaneous clearance confirmed - **Monitor INR, bilirubin, albumin** — watch for progression to acute liver failure - **Avoid hepatotoxins** (alcohol, NSAIDs, acetaminophen in high doses) - **Screen for HBV and HIV** co-infection **Mnemonic: WAIT in Acute HCV** - **W** — Watch for spontaneous clearance (8–12 weeks) - **A** — Admit if severe (monitor synthetic function) - **I** — Interferon is obsolete - **T** — Treat with DAAs only if HCV RNA persists at 12 weeks *Reference: AASLD/IDSA HCV Guidance 2020; Harrison's Principles of Internal Medicine, 21st ed., Chapter on Viral Hepatitis.*